Cargando…

Limited Clinical and Diagnostic Utility of Circulating Tumor DNA Detection in Patients with Early-Stage Well-Differentiated Thyroid Cancer: Comparison with Benign Thyroid Nodules and Healthy Individuals

Limited data are available on the diagnostic utility of circulating tumor DNA (ctDNA) in early-stage thyroid cancers for BRAF, KRAS, NRAS, and TERT promoter mutations, which are known detectable markers for thyroid cancers. Here, we analyzed the above driver mutations in ctDNA and matched neoplastic...

Descripción completa

Detalles Bibliográficos
Autores principales: Suh, Yong Joon, Kwon, Mi Jung, Noh, Hye-Mi, Lee, Hong Kyu, Ra, Yong Joon, Kim, Nan Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065614/
https://www.ncbi.nlm.nih.gov/pubmed/33915745
http://dx.doi.org/10.3390/healthcare9040386
_version_ 1783682382392459264
author Suh, Yong Joon
Kwon, Mi Jung
Noh, Hye-Mi
Lee, Hong Kyu
Ra, Yong Joon
Kim, Nan Young
author_facet Suh, Yong Joon
Kwon, Mi Jung
Noh, Hye-Mi
Lee, Hong Kyu
Ra, Yong Joon
Kim, Nan Young
author_sort Suh, Yong Joon
collection PubMed
description Limited data are available on the diagnostic utility of circulating tumor DNA (ctDNA) in early-stage thyroid cancers for BRAF, KRAS, NRAS, and TERT promoter mutations, which are known detectable markers for thyroid cancers. Here, we analyzed the above driver mutations in ctDNA and matched neoplastic tissues from patients with early-stage thyroid cancers in order to investigate diagnostic utility of circulating markers in distinguishing from other mimicking thyroid lesions and healthy individuals. In total, 73 matched neoplastic tissue and plasma samples [thyroid cancers (n = 62), benign thyroid disorders (n = 8), and parathyroid lesions (n = 3)] and 54 plasma samples from healthy individuals (as controls) were analyzed for BRAF, KRAS, NRAS, and TERT promoter mutations using peptide nucleic acid clamp real-time PCR. Although only one patient with an indeterminate lesion on thyroid cytology showed KRAS mutation (codon 146) in the preoperative plasma, that KRAS mutation was not identified in the stage I papillary thyroid carcinoma tissue. In the remaining 72 plasma samples, no other mutations were identified in BRAF, NRAS, and TERT promoter genes. The concordance rates of mutational results between the plasma and tumor tissue or metastatic lymph node were very low. One (1.9%) of the 54 healthy individuals harbored a KRAS mutation in the plasma samples. The ctDNA results did not represent the mutational profile of primary or metastatic thyroid cancers, warranting a caution for interpretation. The clinical utility of BRAF, KRAS, NRAS, and TERT promoter mutation analysis on ctDNA appears to be limited to early-stage thyroid cancers.
format Online
Article
Text
id pubmed-8065614
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80656142021-04-25 Limited Clinical and Diagnostic Utility of Circulating Tumor DNA Detection in Patients with Early-Stage Well-Differentiated Thyroid Cancer: Comparison with Benign Thyroid Nodules and Healthy Individuals Suh, Yong Joon Kwon, Mi Jung Noh, Hye-Mi Lee, Hong Kyu Ra, Yong Joon Kim, Nan Young Healthcare (Basel) Article Limited data are available on the diagnostic utility of circulating tumor DNA (ctDNA) in early-stage thyroid cancers for BRAF, KRAS, NRAS, and TERT promoter mutations, which are known detectable markers for thyroid cancers. Here, we analyzed the above driver mutations in ctDNA and matched neoplastic tissues from patients with early-stage thyroid cancers in order to investigate diagnostic utility of circulating markers in distinguishing from other mimicking thyroid lesions and healthy individuals. In total, 73 matched neoplastic tissue and plasma samples [thyroid cancers (n = 62), benign thyroid disorders (n = 8), and parathyroid lesions (n = 3)] and 54 plasma samples from healthy individuals (as controls) were analyzed for BRAF, KRAS, NRAS, and TERT promoter mutations using peptide nucleic acid clamp real-time PCR. Although only one patient with an indeterminate lesion on thyroid cytology showed KRAS mutation (codon 146) in the preoperative plasma, that KRAS mutation was not identified in the stage I papillary thyroid carcinoma tissue. In the remaining 72 plasma samples, no other mutations were identified in BRAF, NRAS, and TERT promoter genes. The concordance rates of mutational results between the plasma and tumor tissue or metastatic lymph node were very low. One (1.9%) of the 54 healthy individuals harbored a KRAS mutation in the plasma samples. The ctDNA results did not represent the mutational profile of primary or metastatic thyroid cancers, warranting a caution for interpretation. The clinical utility of BRAF, KRAS, NRAS, and TERT promoter mutation analysis on ctDNA appears to be limited to early-stage thyroid cancers. MDPI 2021-04-01 /pmc/articles/PMC8065614/ /pubmed/33915745 http://dx.doi.org/10.3390/healthcare9040386 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Suh, Yong Joon
Kwon, Mi Jung
Noh, Hye-Mi
Lee, Hong Kyu
Ra, Yong Joon
Kim, Nan Young
Limited Clinical and Diagnostic Utility of Circulating Tumor DNA Detection in Patients with Early-Stage Well-Differentiated Thyroid Cancer: Comparison with Benign Thyroid Nodules and Healthy Individuals
title Limited Clinical and Diagnostic Utility of Circulating Tumor DNA Detection in Patients with Early-Stage Well-Differentiated Thyroid Cancer: Comparison with Benign Thyroid Nodules and Healthy Individuals
title_full Limited Clinical and Diagnostic Utility of Circulating Tumor DNA Detection in Patients with Early-Stage Well-Differentiated Thyroid Cancer: Comparison with Benign Thyroid Nodules and Healthy Individuals
title_fullStr Limited Clinical and Diagnostic Utility of Circulating Tumor DNA Detection in Patients with Early-Stage Well-Differentiated Thyroid Cancer: Comparison with Benign Thyroid Nodules and Healthy Individuals
title_full_unstemmed Limited Clinical and Diagnostic Utility of Circulating Tumor DNA Detection in Patients with Early-Stage Well-Differentiated Thyroid Cancer: Comparison with Benign Thyroid Nodules and Healthy Individuals
title_short Limited Clinical and Diagnostic Utility of Circulating Tumor DNA Detection in Patients with Early-Stage Well-Differentiated Thyroid Cancer: Comparison with Benign Thyroid Nodules and Healthy Individuals
title_sort limited clinical and diagnostic utility of circulating tumor dna detection in patients with early-stage well-differentiated thyroid cancer: comparison with benign thyroid nodules and healthy individuals
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065614/
https://www.ncbi.nlm.nih.gov/pubmed/33915745
http://dx.doi.org/10.3390/healthcare9040386
work_keys_str_mv AT suhyongjoon limitedclinicalanddiagnosticutilityofcirculatingtumordnadetectioninpatientswithearlystagewelldifferentiatedthyroidcancercomparisonwithbenignthyroidnodulesandhealthyindividuals
AT kwonmijung limitedclinicalanddiagnosticutilityofcirculatingtumordnadetectioninpatientswithearlystagewelldifferentiatedthyroidcancercomparisonwithbenignthyroidnodulesandhealthyindividuals
AT nohhyemi limitedclinicalanddiagnosticutilityofcirculatingtumordnadetectioninpatientswithearlystagewelldifferentiatedthyroidcancercomparisonwithbenignthyroidnodulesandhealthyindividuals
AT leehongkyu limitedclinicalanddiagnosticutilityofcirculatingtumordnadetectioninpatientswithearlystagewelldifferentiatedthyroidcancercomparisonwithbenignthyroidnodulesandhealthyindividuals
AT rayongjoon limitedclinicalanddiagnosticutilityofcirculatingtumordnadetectioninpatientswithearlystagewelldifferentiatedthyroidcancercomparisonwithbenignthyroidnodulesandhealthyindividuals
AT kimnanyoung limitedclinicalanddiagnosticutilityofcirculatingtumordnadetectioninpatientswithearlystagewelldifferentiatedthyroidcancercomparisonwithbenignthyroidnodulesandhealthyindividuals